Baxter International Inc (BAX)
35.17
-0.26
(-0.73%)
USD |
NYSE |
May 16, 16:00
35.28
+0.11
(+0.31%)
After-Hours: 20:00
Baxter International Research and Development Expense (Quarterly): 176.00M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 176.00M |
December 31, 2023 | 172.00M |
September 30, 2023 | 166.00M |
June 30, 2023 | 165.00M |
March 31, 2023 | 164.00M |
December 31, 2022 | 154.00M |
September 30, 2022 | 151.00M |
June 30, 2022 | 148.00M |
March 31, 2022 | 150.00M |
December 31, 2021 | 135.00M |
September 30, 2021 | 129.00M |
June 30, 2021 | 139.00M |
March 31, 2021 | 128.00M |
December 31, 2020 | 135.00M |
September 30, 2020 | 123.00M |
June 30, 2020 | 117.00M |
March 31, 2020 | 146.00M |
December 31, 2019 | 156.00M |
September 30, 2019 | 144.00M |
June 30, 2019 | 166.00M |
March 31, 2019 | 129.00M |
December 31, 2018 | 175.00M |
September 30, 2018 | 166.00M |
June 30, 2018 | 174.00M |
March 31, 2018 | 140.00M |
Date | Value |
---|---|
December 31, 2017 | 183.00M |
September 30, 2017 | 150.00M |
June 30, 2017 | 155.00M |
March 31, 2017 | 127.00M |
December 31, 2016 | 156.00M |
September 30, 2016 | 159.00M |
June 30, 2016 | 195.00M |
March 31, 2016 | 136.00M |
December 31, 2015 | 161.00M |
September 30, 2015 | 148.00M |
June 30, 2015 | 151.00M |
March 31, 2015 | 143.00M |
December 31, 2014 | 156.00M |
September 30, 2014 | 149.00M |
June 30, 2014 | 322.00M |
March 31, 2014 | 309.00M |
December 31, 2013 | -187.00M |
September 30, 2013 | 277.00M |
June 30, 2013 | 273.00M |
March 31, 2013 | 246.00M |
December 31, 2012 | 216.00M |
September 30, 2012 | 290.00M |
June 30, 2012 | 306.00M |
March 31, 2012 | 269.00M |
December 31, 2011 | 254.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
117.00M
Minimum
Jun 2020
176.00M
Maximum
Mar 2024
148.20M
Average
149.00M
Median
Research and Development Expense (Quarterly) Benchmarks
LeMaitre Vascular Inc | 4.092M |
Becton Dickinson & Co | 299.00M |
Boston Scientific Corp | 366.00M |
ResMed Inc | 77.07M |
Outset Medical Inc | 12.64M |